The effect of non-competitive NMDA receptor antagonist MK-801 on neuronal activity in rodent prefrontal cortex: An animal model for cognitive symptoms of schizophrenia

Journal of Physiology Paris

Volumn 107, Issue 6, 2013, Pages 448-451

  Blot, Kevin ^a   Bai, Jing ^a   Otani, Satoru ^a,b  

^a Université Pierre et Marie Curie   (France)

^b RYOTOKUJI UNIVERSITY   (Japan)

Author keywords

Hippocampo prefrontal cortex pathway; In vivo electrophysiology; Long term potentiation; LTP; MK 801; NMDA receptor hypofunction; Schizophrenia

Indexed keywords

DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; BRAIN NERVE CELL; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE MODEL; HIPPOCAMPAL CA1 REGION; HUMAN; INTERNEURON; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MOLECULAR DYNAMICS; NERVE CELL PLASTICITY; NERVE CELL STIMULATION; NEUROPATHOLOGY; NONHUMAN; PREFRONTAL CORTEX; RECEPTOR BLOCKING; RODENT MODEL; SCHIZOPHRENIA; SPATIAL MEMORY; WORKING MEMORY;

HIPPOCAMPO-PREFRONTAL CORTEX PATHWAY; IN VIVO ELECTROPHYSIOLOGY; LONG-TERM POTENTIATION; LTP; MK-801; NMDA RECEPTOR HYPOFUNCTION; SCHIZOPHRENIA;

ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; PREFRONTAL CORTEX; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84888062854     PISSN: 09284257     EISSN: 17697115     Source Type: Journal    
DOI: 10.1016/j.jphysparis.2013.04.003     Document Type: Article

References (62)

1. Andreasen N.C., Rezai K., Alliger R., Swayze V.W., Flaum M., Kirchner P., Cohen G., O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch. Gen. Psychiatry 1992, 49:943-958.
2. Baudin A., Blot K., Verney C., Estevez L., Santa-Maria J., Gressens P., Giros B., Otani S., Dauge V., Naudon L. Maternal deprivation induces deficits in temporal memory and cognitive flexibility and exaggerates synaptic plasticity in the rat medial prefrontal cortex. Neurobiol. Learn. Mem. 2012.
3. Bear M.F. Bidirectional synaptic plasticity: from theory to reality. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2003, 358:649-655.
4. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
5. Birrell J.M., Brown V.J. Medial frontal cortex mediates perceptual attentional set shifting in the rat. J. Neurosci. 2000, 20:4320-4324.
6. Bliss T.V., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
7. Blot K. Plasticité neuronale dans le cortex préfrontal du rat induite par un antagoniste non compétitif des récepteurs NMDA: vers un modèle des symptÔmes cognitifs de la schizophrénie. Thèse de Neurosciences 2013, Université Paris Descartes, France,
8. Blot, K., Kimura, S., Kemp, A., Tzavara, E., Giros, B., Otani, S., 2012. The effect of non-competitive NMDA receptor antagonist MK801 on hippocampus-prefrontal cortex synaptic responses and executive cognitive function in rats. In: FENS meeting, 14-18 July, 2012, Barcelona. <. http://fens.ekonnect.co/FENS_331/poster_34734/program.aspx.
9. Bubenikova-Valesova V., Horacek J., Vrajova M., Hoschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev. 2008, 32:1014-1023.
10. Churchwell J.C., Kesner R.P. Hippocampal-prefrontal dynamics in spatial working memory: interactions and independent parallel processing. Behav. Brain Res. 2011, 225:389-395.
11. Egerton A., Reid L., McKerchar C.E., Morris B.J., Pratt J.A. Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl) 2005, 179:77-84.
12. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 2000, 14:1-21.
13. Floresco S.B., Seamans J.K., Phillips A.G. Selective roles for hippocampal, prefrontal cortical, and ventral striatal circuits in radial-arm maze tasks with or without a delay. J. Neurosci. 1997, 17:1880-1890.
14. Foster K.A., McLaughlin N., Edbauer D., Phillips M., Bolton A., Constantine-Paton M., Sheng M. Distinct roles of NR2A and NR2B cytoplasmic tails in long-term potentiation. J. Neurosci. 2010, 30:2676-2685.
15. Frantseva M.V., Fitzgerald P.B., Chen R., Moller B., Daigle M., Daskalakis Z.J. Evidence for impaired long-term potentiation in schizophrenia and its relationship to motor skill learning. Cereb Cortex 2008, 18:990-996.
16. Gielen M., Siegler Retchless B., Mony L., Johnson J.W., Paoletti P. Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 2009, 459:703-707.
17. Grunze H.C., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., Greene R.W. NMDA-dependent modulation of CA1 local circuit inhibition. J. Neurosci. 1996, 16:2034-2043.
18. Gurden H., Takita M., Jay T.M. Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J. Neurosci. 2000, 20:RC106.
19. Hasan A., Nitsche M.A., Herrmann M., Schneider-Axmann T., Marshall L., Gruber O., Falkai P., Wobrock T. Impaired long-term depression in schizophrenia: a cathodal tDCS pilot study. Brain Stimul. 2012.
20. Hasan A., Nitsche M.A., Rein B., Schneider-Axmann T., Guse B., Gruber O., Falkai P., Wobrock T. Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav. Brain Res. 2012, 224:15-22.
21. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 2007, 27:11496-11500.
22. Izaki Y., Hori K., Nomura M. Disturbance of rat lever-press learning by hippocampo-prefrontal disconnection. Brain Res. 2000, 860:199-202.
23. Jackson M.E., Homayoun H., Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc. Natl. Acad. Sci. USA 2004, 101:8467-8472.
24. Jay T.M., Witter M.P. Distribution of hippocampal CA1 and subicular efferents in the prefrontal cortex of the rat studied by means of anterograde transport of Phaseolus vulgaris-leucoagglutinin. J. Comp. Neurol. 1991, 313:574-586.
25. Jay T.M., Thierry A.M., Wiklund L., Glowinski J. Excitatory amino acid pathway from the hippocampus to the prefrontal cortex. Contribution of AMPA receptors in hippocampo-prefrontal cortex transmission. Eur. J. Neurosci. 1992, 4:1285-1295.
26. Jay T.M., Burette F., Laroche S. NMDA receptor-dependent long-term potentiation in the hippocampal afferent fibre system to the prefrontal cortex in the rat. Eur. J. Neurosci. 1995, 7:247-250.
27. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999, 20:201-225.
28. Jessen F., Scheef L., Germeshausen L., Tawo Y., Kockler M., Kuhn K.U., Maier W., Schild H.H., Heun R. Reduced hippocampal activation during encoding and recognition of words in schizophrenia patients. Am. J. Psychiatry 2003, 160:1305-1312.
29. Jodo E., Suzuki Y., Katayama T., Hoshino K.Y., Takeuchi S., Niwa S., Kayama Y. Activation of medial prefrontal cortex by phencyclidine is mediated via a hippocampo-prefrontal pathway. Cereb Cortex 2005, 15:663-669.
30. Kinney J.W., Davis C.N., Tabarean I., Conti B., Bartfai T., Behrens M.M. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J. Neurosci. 2006, 26:1604-1615.
31. Kocsis B. Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol. Psychiatry 2012, 71:987-995.
32. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
33. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
34. Laroche S., Jay T.M., Thierry A.M. Long-term potentiation in the prefrontal cortex following stimulation of the hippocampal CA1/subicular region. Neurosci. Lett. 1990, 114:184-190.
35. Lipska B.K. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J. Psychiatry Neurosci. 2004, 29:282-286.
36. Lopez-Gil X., Babot Z., Amargos-Bosch M., Sunol C., Artigas F., Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32:2087-2097.
37. Lorrain D.S., Baccei C.S., Bristow L.J., Anderson J.J., Varney M.A. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 2003, 117:697-706.
38. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch. Neurol. Psychiatry 1959, 81:363-369.
39. Machado-Vieira R., Ibrahim L., Henter I.D., Zarate C.A. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol. Biochem. Behav. 2012, 100:678-687.
40. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17:141-150.
41. Markram H., Toledo-Rodriguez M., Wang Y., Gupta A., Silberberg G., Wu C. Interneurons of the neocortical inhibitory system. Nat. Rev. Neurosci. 2004, 5:793-807.
42. Matsumoto M., Shikanai H., Togashi H., Izumi T., Kitta T., Hirata R., Yamaguchi T., Yoshioka M. Characterization of clozapine-induced changes in synaptic plasticity in the hippocampal-mPFC pathway of anesthetized rats. Brain Res. 2008, 1195:50-55.
43. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
44. Moser E.I., Krobert K.A., Moser M.B., Morris R.G. Impaired spatial learning after saturation of long-term potentiation. Science 1998, 281:2038-2042.
45. Nicholls R.E., Alarcon J.M., Malleret G., Carroll R.C., Grody M., Vronskaya S., Kandel E.R. Transgenic mice lacking NMDAR-dependent LTD exhibit deficits in behavioral flexibility. Neuron 2008, 58:104-117.
46. Ragland J.D., Yoon J., Minzenberg M.J., Carter C.S. Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism. Int. Rev. Psychiatry 2007, 19:417-427.
47. Roenker N.L., Gudelsky G.A., Ahlbrand R., Horn P.S., Richtand N.M. Evidence for involvement of nitric oxide and GABA(B) receptors in MK-801- stimulated release of glutamate in rat prefrontal cortex. Neuropharmacology 2012, 63:575-581.
48. Rotaru D.C., Yoshino H., Lewis D.A., Ermentrout G.B., Gonzalez-Burgos G. Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia. J. Neurosci. 2011, 31:142-156.
49. Schafe G.E., Atkins C.M., Swank M.W., Bauer E.P., Sweatt J.D., LeDoux J.E. Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J. Neurosci. 2000, 20:8177-8187.
50. Sesack S.R., Carr D.B., Omelchenko N., Pinto A. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann. NY Acad. Sci. 2003, 1003:36-52.
51. Soyka M., Koch W., Moller H.J., Ruther T., Tatsch K. Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:308-312.
52. Stefani M.R., Groth K., Moghaddam B. Glutamate receptors in the rat medial prefrontal cortex regulate set-shifting ability. Behav. Neurosci. 2003, 117:728-737.
53. Suzuki Y., Jodo E., Takeuchi S., Niwa S., Kayama Y. Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats. Neuroscience 2002, 114:769-779.
54. Uylings H.B., Groenewegen H.J., Kolb B. Do rats have a prefrontal cortex?. Behav. Brain Res. 2003, 146:3-17.
55. Volz H., Gaser C., Hager F., Rzanny R., Ponisch J., Mentzel H., Kaiser W.A., Sauer H. Decreased frontal activation in schizophrenics during stimulation with the continuous performance test - a functional magnetic resonance imaging study. Eur. Psychiatry 1999, 14:17-24.
56. Wang G.W., Cai J.X. Disconnection of the hippocampal-prefrontal cortical circuits impairs spatial working memory performance in rats. Behav. Brain Res. 2006, 175:329-336.
57. Wang G.W., Cai J.X. Reversible disconnection of the hippocampal-prelimbic cortical circuit impairs spatial learning but not passive avoidance learning in rats. Neurobiol. Learn. Mem. 2008, 90:365-373.
58. Wedzony K., Klimek V., Golembiowska K. MK-801 elevates the extracellular concentration of dopamine in the rat prefrontal cortex and increases the density of striatal dopamine D1 receptors. Brain Res. 1993, 622:325-329.
59. Wilson F.A., O'Scalaidhe S.P., Goldman-Rakic P.S. Functional synergism between putative gamma-aminobutyrate-containing neurons and pyramidal neurons in prefrontal cortex. Proc. Natl. Acad. Sci. USA 1994, 91:4009-4013.
60. Wong T.P., Howland J.G., Robillard J.M., Ge Y., Yu W., Titterness A.K., Brebner K., Liu L., Weinberg J., Christie B.R., Phillips A.G., Wang Y.T. Hippocampal long-term depression mediates acute stress-induced spatial memory retrieval impairment. Proc. Natl. Acad. Sci. USA 2007, 104:11471-11476.
61. Xi D., Keeler B., Zhang W., Houle J.D., Gao W.J. NMDA receptor subunit expression in GABAergic interneurons in the prefrontal cortex: application of laser microdissection technique. J. Neurosci. Methods 2009, 176:172-181.
62. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.